Literature DB >> 16191216

Vascular factors in Alzheimer's disease.

Raj N Kalaria1.   

Abstract

Vascular involvement in Alzheimer disease (AD) is not necessarily coincident. Current evidence suggests the neuropathology of Alzheimer type of dementia comprises more than amyloid plaques and neurofibrillary tangles. At least a third of recognized AD cases may exhibit cerebrovascular pathology, which also constitutes distinct small vessel disease. Cerebral amyloid angiopathy, microvascular degeneration affecting the cerebral endothelium and smooth muscle cells, basal lamina alterations, hyalinosis, and fibrosis are frequently evident in AD. These changes may be accompanied by perivascular denervation that is causal in the cognitive decline of AD. In addition, amyloid beta protein appears directly involved in the degeneration of both the larger perforating arterial vessels as well as cerebral capillaries, which represent the blood-brain barrier. The cerebrovascular pathology in AD also encompasses macro- and micro-infarctions, hemorrhages, lacunas, and ischemic white-matter changes. An interaction of both perivascular mediators and derived factors would perturb the brain vasculature. Peripheral vascular factors such as long-standing hypertension, atrial fibrillation, coronary or carotid artery disease, and diabetes mellitus are also apparent in AD. These factors would modify the cerebral circulation such that a sustained hypoperfusion or oligemia is impacted upon the aging processes to induce the characteristic pathology.

Entities:  

Mesh:

Year:  2003        PMID: 16191216     DOI: 10.1017/S1041610203008950

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  23 in total

1.  Cerebral embolism and Alzheimer's disease.

Authors:  Miia Kivipelto; Alina Solomon
Journal:  BMJ       Date:  2006-05-13

2.  Oligemic hypoperfusion differentially affects tau and amyloid-{beta}.

Authors:  Maya A Koike; Kim N Green; Mathew Blurton-Jones; Frank M Laferla
Journal:  Am J Pathol       Date:  2010-05-14       Impact factor: 4.307

3.  Hypertension is associated with cognitive decline in elderly people at high risk for dementia.

Authors:  Michael Wysocki; Xiaodong Luo; James Schmeidler; Karen Dahlman; Gerson T Lesser; Hillel Grossman; Vahram Haroutunian; Michal Schnaider Beeri
Journal:  Am J Geriatr Psychiatry       Date:  2012-02       Impact factor: 4.105

Review 4.  Alzheimer's disease, brain immune privilege and memory: a hypothesis.

Authors:  Y I Arshavsky
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

5.  Kidney dysfunction and cognitive decline in women.

Authors:  Imran Sajjad; Francine Grodstein; Jae H Kang; Gary C Curhan; Julie Lin
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-12       Impact factor: 8.237

6.  Nonmedical treatment of patients with dementia.

Authors:  Edmund Howe
Journal:  Innov Clin Neurosci       Date:  2011-07

7.  An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease.

Authors:  Lidia Sarro; Nirubol Tosakulwong; Christopher G Schwarz; Jonathan Graff-Radford; Scott A Przybelski; Timothy G Lesnick; Samantha M Zuk; Robert I Reid; Mekala R Raman; Bradley F Boeve; Tanis J Ferman; David S Knopman; Giancarlo Comi; Massimo Filippi; Melissa E Murray; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Clifford R Jack; Kejal Kantarci
Journal:  Alzheimers Dement       Date:  2016-08-10       Impact factor: 21.566

8.  Imaging cerebral blood flow in the cognitively normal aging brain with arterial spin labeling: implications for imaging of neurodegenerative disease.

Authors:  Charles Lee; Oscar L Lopez; James T Becker; Cyrus Raji; Weiying Dai; Lewis H Kuller; H Michael Gach
Journal:  J Neuroimaging       Date:  2009-03-09       Impact factor: 2.486

9.  Sustained attention is associated with left ventricular ejection fraction in older adults with heart disease.

Authors:  Beth A Jerskey; Ronald A Cohen; Angela L Jefferson; Karin F Hoth; Andreana P Haley; John J Gunstad; Daniel E Forman; Lawrence H Sweet; Athena Poppas
Journal:  J Int Neuropsychol Soc       Date:  2009-01       Impact factor: 2.892

Review 10.  Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.

Authors:  Elisa Zuccarello; Erica Acquarone; Elisa Calcagno; Elentina K Argyrousi; Shi-Xian Deng; Donald W Landry; Ottavio Arancio; Jole Fiorito
Journal:  Biochem Pharmacol       Date:  2020-01-21       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.